Loading...
Loading...
MNKD| Name | Value |
|---|---|
| Revenues | 36.1M |
| Cost of Revenue | 16.1M |
| Gross Profit | 19.9M |
| Operating Expense | 29.3M |
| Operating I/L | -9.3M |
| Other Income/Expense | -8.6M |
| Interest Income | 1.0M |
| Pretax | -17.9M |
| Income Tax Expense | 5.3M |
| Net Income/Loss | -23.2M |
MannKind Corporation is a biopharmaceutical company specializing in inhaled therapeutic products for endocrine and orphan lung diseases. Its flagship product, Afrezza, is an inhaled insulin designed to enhance glycemic control in adults with diabetes. The company also markets Thyquidity for the treatment of hypothyroidism. MannKind has a license and collaboration agreement with United Therapeutics Corporation and a partnership with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), a synthetic form of human vasoactive intestinal peptide to combat inflammatory conditions.
